



RECEIVED

MAY 08 2002

GR JP 3000

Docket No.: LUD-5722/10111925

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Ronaldo A. Nagem, et al.

Application No.: 10/050,552

Group Art Unit: 1641

Filed: January 18, 2002

Examiner: Not Yet Assigned

For: CRYSTAL STRUCTURE OF HUMAN  
INTERLEUKIN-22

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents  
Washington, DC 20231

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO-1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned.

A copy of each reference on PTO-1449 is attached.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. LUD-5722/10111925. A duplicate copy of this paper is enclosed.

Dated: May 2, 2002

Respectfully submitted,

By

Einar Stole

Registration No.: 47,272

FULBRIGHT & JAWORSKI L.L.P.

Market Square

801 Pennsylvania Avenue, N.W.

Washington, DC 20004-2615

(202) 662-0200

(202) 662-4643 (Fax)

Attorneys for Applicant

# 5 / I / S  
5/9/02  
RECEIVED  
AUG 30 2002  
TECH CENTER 1600/2900  
MAY 03 2002  
RECEIVED  
TECH CENTER 1600/2900



Docket No.: LUD-5722/10111925  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Patent Application of:  
Rosaldo A. Nagem, et al.

Application No.: 10/050,552

Group Art Unit: 1641

Filed: January 18, 2002

Examiner: Not Yet Assigned

For: CRYSTAL STRUCTURE OF HUMAN  
INTERLEUKIN-22

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
Washington, DC 20231

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO-1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned.

A copy of each reference on PTO-1449 is attached.


The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. LUD-5722/10111925. A duplicate copy of this paper is enclosed.

Dated: May 2, 2002

Respectfully submitted,

By   
Einar Stole

Registration No.: 47,272  
FULBRIGHT & JAWORSKI L.L.P.  
Market Square  
801 Pennsylvania Avenue, N.W.  
Washington, DC 20004-2615  
(202) 662-0200  
(202) 662-4643 (Fax)  
Attorneys for Applicant



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2	Application Number	10/050,552
				Filing Date	January 18, 2002
				First Named Inventor	Ronaldo A. Nagem
				Art Unit	1641
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	LUD-5722/10111925

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	5,835,382	11-10-1998	Wilson <i>et al.</i>	
	AB	6,090,609	07-19-2000	Luo <i>et al.</i>	
	AC	6,242,201	06-05-2001	Lane <i>et al.</i>	
	AD	6,251,620	06-26-2001	Hatada <i>et al.</i>	
	AE	6,273,598	08-14-2001	Keck <i>et al.</i>	
	AF	6,303,287	10-16-2001	Kim <i>et al.</i>	
	AG				

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	BA	WO 00/24758	05-04-2000	Ludwig Institute for Cancer Research		

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See attached Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	Table of Contents - special emphasis on COLIGAN <i>et al.</i> , <i>Current Protocols in Immunology</i> , 1(2), Chapter 5 (1991)	
	CB	COOKSON, W., "The alliance of genes and environment in asthma and allergy", <i>Nature</i> , 402s: B5-B11 (2000)	
	CC	DUMOUTIER, L. <i>et al.</i> , "Cloning and Characterization of IL-10-Related T Cell-Derived Inducible Factor (IL-TIF), a Novel Cytokine Structurally Related to IL-10 and Inducible by IL-9", <i>J. Immunol.</i> 164: 1814-1819 (2000)	
	CD	DUMOUTIER, L. <i>et al.</i> , "Human interleukin-10-related T cell-derived inducible factor: Molecular cloning and functional characterization as an hepatocyte-stimulating factor", <i>Proc. Natl. Acad. Sci. U.S.A.</i> 97: 10144-10149 (2000)	
	CE	DUMOUTIER, L. <i>et al.</i> , "IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes", <i>Genes and Immunity</i> 1: 488-494 (2000)	
	CF	ESNOUF, R., "An extensively modified version of MolScript that includes greatly enhanced coloring capabilities", <i>J. Mol. Graph.</i> 15: 133-138 (1997)	
	CG	FITZLOFF, J., "The Impact of Biotechnology on Analytical Methodology", <i>Biotechnology and Pharmacy - Chapter 5</i> : 97-115, (edited by Pezzuto <i>et al.</i> ) (1993)	
	CH	KOTENKO, S., <i>et al.</i> , "Identification and functional characterization of a second chain of the interleukin-10 receptor complex", <i>EMBO J.</i> 16(19): 5894-5903 (1997)	
	CI	KOTENKO, S., <i>et al.</i> , "Identification of the Functional Interleukin-22 (IL-22) Receptor Complex", <i>J. Biol. Chem.</i> 276: 2725-2732 (2001)	
	CJ	KRAULIS, P., "MolScript: a program to produce both detailed and schematic plots of protein structures", <i>J. Appl. Cryst.</i> 24: 946-950 (1991)	

RECEIVED

AUG 30 2002

TECH CENTER 1600/2900

PTO/SB/08B (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

Complete if Known

Application Number	10/050,552
Filing Date	January 18, 2002
First Named Inventor	Ronald A. Nagem
Group Art Unit	1641
Examiner Name	Not Yet Assigned
Attorney Docket Number	LUD-5722/10111925

CK	LASKOWSKI, R., <i>et al.</i> , "Procheck: a program to check the stereochemical quality of protein structures", <i>J. Appl. Cryst.</i> 26: 283-291 (1993)	
CL	LEVITT, R., <i>et al.</i> , "IL-9 pathway in asthma: New therapeutic targets for allergic inflammatory disorders", <i>J. Allergy Clin. Immunol.</i> 103: 485-491 (1999)	
CM	MCLANE, M., <i>et al.</i> , "Interleukin-9 Promotes Allergen-Induced Eosinophilic Inflammation and Airway Hyperresponsiveness in Transgenic Mice", <i>Am. J. Respir. Cell Mol. Biol.</i> 19: 713-720 (1998)	
CN	MORGAN, B., <i>et al.</i> , "Approaches to the Discovery of Non-Peptide Ligands for Peptide Receptors and Peptidases", (edited by Vinick) <i>In: Ann. Rep. Med. Chem.</i> 24: 243-252 (1989)	
CO	POLIKARPOV, I., <i>et al.</i> , "Set-up and Experimental Parameters of the Protein Crystallography Beamline at the Brazilian National Synchrotron Laboratory", <i>J. Synchrotron Rad.</i> 5: 72-76 (1998)	
CP	POLIKARPOV, I., <i>et al.</i> , "The protein crystallography beamline at LNLS, the Brazilian National Synchrotron Light Source", <i>Nucl. Instrum. And Methods</i> , A405: 159-164 (1998)	
CQ	SIMON, R., <i>et al.</i> , "Peptoids: A modular approach to drug discovery", <i>Proc. Natl. Acad. Sci. U.S. A.</i> 89: 9367-9371 (1992)	
CR	TEMANN, U., <i>et al.</i> , "Expression of Interleukin 9 in the Lungs of Transgenic Mice Causes Airway Inflammation, Mast Cell Hyperplasia, and Bronchial Hyperresponsiveness", <i>J. Exp. Med.</i> 188(7): 1307-1320 (1998)	
CS	XIE, M., <i>et al.</i> , "Interleukin (IL-22), a Novel Human Cytokine That Signals through the Interferon Receptor-related Proteins CRF2-4 and IL-22R", <i>J. Biol. Chem.</i> 275(40): 31335-31339 (2000)	
CT	ZDANOV, A., <i>et al.</i> , "Crystal structure of interleukin-10 reveals the functional dimer with an unexpected topological similarity to interferon $\gamma$ ", <i>Structure</i> 3: 591-601 (1995)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.